The trajectory of Viagra presents a complex case for stakeholders in the drug sector. While initially a blockbuster success, producing huge profits, the exclusivity lapse and the subsequent entry of cheaper versions have significantly affected revenue. This poses questions about the ongoing sustainability of analogous therapeutic developments and s